Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Olmesartan medoxomil: current status of its use in monotherapy Brunner HRVasc Health Risk Manag 2006[]; 2 (4): 327-40Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks' treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. The drug was well tolerated with a similar adverse event profile to placebo. In patients with type 2 diabetes, olmesartan medoxomil reduced renal vascular resistance, increased renal perfusion, and reduced oxidative stress. In several large, randomized, double-blind trials, olmesartan medoxomil 20 mg has been shown to be significantly more effective, in terms of primary endpoints, than recommended doses of losartan, valsartan, irbesartan, or candesartan cilexetil, and to provide better 24 h BP protection. Olmesartan medoxomil was at least as effective as amlodipine, felodipine and atenolol, and significantly more effective than captopril. The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes.|Adrenergic beta-Antagonists/therapeutic use[MESH]|Angiotensin II Type 1 Receptor Blockers/adverse effects/economics/*therapeutic use[MESH]|Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH]|Antihypertensive Agents/adverse effects/economics/*therapeutic use[MESH]|Blood Pressure/*drug effects[MESH]|Calcium Channel Blockers/therapeutic use[MESH]|Cost-Benefit Analysis[MESH]|Drug Costs[MESH]|Humans[MESH]|Hypertension/*drug therapy/physiopathology[MESH]|Imidazoles/adverse effects/economics/*therapeutic use[MESH]|Olmesartan Medoxomil[MESH]|Randomized Controlled Trials as Topic/methods[MESH]|Research Design[MESH]|Tetrazoles/adverse effects/economics/*therapeutic use[MESH]|Treatment Outcome[MESH] |
